Exelixis partners with Merck for colorectal cancer trial

May 19, 2026 8:00 AM

Exelixis Inc. (NASDAQ: EXEL) entered into a clinical development collaboration with Merck to conduct STELLAR-316, a phase 3 trial testing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found